No quarterly revenue total was found in SIGYN THERAPEUTICS, INC.'s SEC filings.
Sigyn Therapeutics, Inc. (SIGY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. As of Sep 30, 2025 it held $85,571 in cash and investments and $3.9 million in total debt.
Revenue
—
Net income
$-578,503
+51.7% vs year-ago quarter
Operating cash flow
$-199,326
-21.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.36
+61.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.61M
-0.0% vs year-ago quarter
Net cash
$-3.77M
Q3 FY2025
Operating margin
-7019.1%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SIGY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Beverly Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642159
- Former names
- Reign Resources Corp (until Oct 23, 2020); Reign Sapphire Corp (until May 12, 2020)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
|---|---|---|---|---|---|
| Operating income | -$386,529 | -$469,513 | -$546,059 | -$478,010 | -$808,458 |
| Net income | -$578,503 | -$1.5M | -$668,564 | -$522,818 | -$1.2M |
| Diluted EPS | -$0.36 | -$0.90 | -$0.42 | -$0.33 | -$0.94 |
| Operating cash flow | -$199,326 | -$152,436 | -$294,446 | -$290,218 | -$163,812 |
| Total assets | $135,571 | $51,759 | $244,309 | $213,719 | $427,438 |
| Total liabilities | $6.1M | $5.5M | $5.2M | $4.7M | $4.4M |
| Stockholders' equity | -$5.9M | -$5.4M | -$4.9M | -$4.5M | -$3.9M |
| Cash and investments | $85,571 | $459 | $12,895 | $12,144 | $164,788 |
| Total debt | $3.9M | $2.8M | $2.7M | $2.3M | $2.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 20, 2026 | Feb 20, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Sep 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Aug 15, 2025 | Aug 14, 2025 |
| 10-Q | Quarterly report | May 20, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
All 175 Sigyn Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.